Clinical features of patients with pancreatic ductal adenocarcinoma with a history of other primary malignancies: A retrospective analysis

被引:1
作者
Hayashi, Hironori [1 ]
Amaya, Koji [1 ]
Tokoro, Tomokazu [1 ]
Mori, Kosuke [1 ]
Takenaka, Shunsuke [1 ]
Sugimoto, Yuya [1 ]
Kitano, Yuto [1 ]
Kurata, Toru [1 ]
Kawai, Shunsuke [1 ]
Hirose, Atsushi [1 ]
Tsukada, Tomoya [1 ]
Kaji, Masahide [1 ]
Shimizu, Koichi [2 ]
Maeda, Kiichi [1 ]
机构
[1] Toyama Prefectural Cent Hosp, Dept Surg, 2-2-78 Nishi Nagae, Toyama 9308550, Japan
[2] Kaga Med Ctr, Dept Surg, Kaga, Ishikawa 9228522, Japan
关键词
cancer genomics; epidemiology; multiple primary malignancies; pancreatic ductal adenocarcinoma; prognosis; surgical treatment; CANCER PATIENTS; ORGANS; IMPACT;
D O I
10.3892/mco.2021.2.335
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Patients with pancreatic ductal adenocarcinoma (PDAC) that have a history of other primary malignancies are not well documented. The current study therefore aimed to evaluate the dinicopathological characteristics of patients with PDAC with or without a history of other primary malignancies. A total of 102 patients with surgically treated PDAC that presented with or without a history of other primary malignancies were retrospectively analyzed. A total of 25 patients (24.5%) had a history of other primary malignancies (age, with history of other primary malignancy vs. without, 74.2 vs. 68.9 years; P=0.005) and the reason for consultation (P<0.001) differed significantly between the groups with a history of other primary malignancies [FloM(+)] and without a history of other primary malignancies [HOMO]. Incidental indications during malignancy follow-up was the most common reason for the diagnosis of PDAC in the HoM(+) group. Conversely, there were no significant differences in the resectability (P=0.645), complete resection rate (P=0.774) and final stage (P=0.474) between the two groups. Disease-free survival was also not significantly different between the two groups (P=0.184). However, overall survival was significantly poorer in the HoM(+) group compared with the HoM(-) group (P=0.003). A history of other primary malignancies was also an independent predictor of poor overall survival (hazard ratio, 2.416; 95% confidence interval, 1.324-4.406; P=0.004). In conclusion, patients with PDAC and a history of other primary malignancies had significantly poorer overall survival than their counterparts, despite no differences in disease-free survival.
引用
收藏
页数:7
相关论文
共 26 条
  • [1] Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
    Adamska, Aleksandra
    Domenichini, Alice
    Falasca, Marco
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (07)
  • [2] Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios
    Asari, Sadaki
    Matsumoto, Ippei
    Toyama, Hirochika
    Shinzeki, Makoto
    Goto, Tadahiro
    Ishida, Jun
    Ajiki, Tetsuo
    Fukumoto, Takumi
    Ku, Yonson
    [J]. SURGERY TODAY, 2016, 46 (05) : 583 - 592
  • [3] Brierley JD., 2017, TNM CLASSIFICATION M, V8th, P930
  • [4] Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
    Bryant, HE
    Schultz, N
    Thomas, HD
    Parker, KM
    Flower, D
    Lopez, E
    Kyle, S
    Meuth, M
    Curtin, NJ
    Helleday, T
    [J]. NATURE, 2005, 434 (7035) : 913 - 917
  • [5] Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
    Buscail, Louis
    Bournet, Barbara
    Cordelier, Pierre
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2020, 17 (03) : 153 - 168
  • [6] Synchronous or metachronous double cancers of the pancreas and other organs: Report on 12 cases
    Eriguchi, N
    Aoyagi, S
    Hara, M
    Okuda, K
    Tamae, T
    Fukuda, S
    Hashino, K
    Sato, S
    Fujiki, K
    Furukawa, S
    Jimi, A
    [J]. SURGERY TODAY-THE JAPANESE JOURNAL OF SURGERY, 2000, 30 (08): : 718 - 721
  • [7] Multiple primaries in pancreatic cancer patients: indicator of a genetic predisposition?
    Gerdes, B
    Ziegler, A
    Ramaswamy, A
    Wild, A
    Langer, P
    Bartsch, DK
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2000, 29 (06) : 999 - 1003
  • [8] Guo MZ, 2014, DISCOV MED, V17, P67
  • [9] The impact of a history of cancer on pancreatic ductal adenocarcinoma survival
    He, Xingkang
    Li, Yue
    Su, Tingting
    Lai, Sanchuan
    Wu, Wenrui
    Chen, Luyi
    Si, Jianmin
    Sun, Leimin
    [J]. UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2018, 6 (06) : 888 - 894
  • [10] Outcomes in patients with pancreatic cancer as a secondary malignancy: a retrospective single-institution study
    Hoshimoto, Sojun
    Hishinuma, Shoichi
    Shirakawa, Hirofumi
    Tomikawa, Moriaki
    Ozawa, Iwao
    Ogata, Yoshiro
    [J]. LANGENBECKS ARCHIVES OF SURGERY, 2019, 404 (08) : 975 - 983